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EdBACKGROUND Limited information exists describing the results of transcatheter aortic valve (TAV) replacement
in patients with bicuspid aortic valve (BAV) disease (TAV-in-BAV).
OBJECTIVES This study sought to evaluate clinical outcomes of a large cohort of patients undergoing TAV-in-BAV.
METHODS We retrospectively collected baseline characteristics, procedural data, and clinical follow-up ﬁndings from
12 centers in Europe and Canada that had performed TAV-in-BAV.
RESULTS A total of 139 patients underwent TAV-in-BAV with the balloon-expandable transcatheter heart valve (THV)
(n ¼ 48) or self-expandable THV (n ¼ 91) systems. Patient mean age and Society of Thoracic Surgeons predicted risk of
mortality scoreswere 78.08.9 years and4.93.4%, respectively. BAV stenosis occurred in65.5%, regurgitation in0.7%,
and mixed disease in 33.8% of patients. Incidence of type 0 BAV was 26.7%; type 1 BAV was 68.3%; and type 2 BAV was
5.0%.Multislice computed tomography (MSCT)-basedTAV sizingwas used in63.5%ofpatients (77.1%balloon-expandable
THV vs. 56.0% self-expandable THV, p ¼ 0.02). Procedural mortality was 3.6%, with TAV embolization in 2.2% and con-
version to surgery in 2.2%. Themean aortic gradient decreased from48.7 16.5mmHg to 11.4 9.9mmHg (p<0.0001).
Post-implantation aortic regurgitation (AR) grade $2 occurred in 28.4% (19.6% balloon-expandable THV vs. 32.2% self-
expandable THV, p ¼ 0.11) but was prevalent in only 17.4% when MSCT-based TAV sizing was performed (16.7% balloon-
expandable THV vs. 17.6% self-expandable THV, p ¼ 0.99). MSCT sizing was associated with reduced AR on multivariate
analysis (odds ratio [OR]: 0.19, 95% conﬁdence intervals [CI]: 0.08 to 0.45; p<0.0001). Thirty-day device safety, success,
and efﬁcacy were noted in 79.1%, 89.9%, and 84.9% of patients, respectively. One-year mortality was 17.5%. Major
vascular complications were associated with increased 1-year mortality (OR: 5.66, 95% CI: 1.21 to 26.43; p ¼ 0.03).
CONCLUSIONS TAV-in-BAV is feasible with encouraging short- and intermediate-term clinical outcomes. Importantly,
a high incidence of post-implantation AR is observed, which appears to be mitigated by MSCT-based TAV sizing. Given
the suboptimal echocardiographic results, further study is required to evaluate long-term efﬁcacy. (J Am Coll Cardiol
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AB BR E V I A T I O N S
AND ACRONYM S
BAV = bicuspid aortic valve
CI = conﬁdence interval
MSCT = multislice computed
tomography
NYHA = New York Heart
Association
OR = odds ratio
SAVR = surgical aortic valve
replacement
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2331B icuspid aortic valve (BAV) is a heritable dis-ease affecting 0.5% to 2% of the generalpopulation, with a strong male predilection
(1–3). BAV stenosis and/or regurgitation is the most
common indication for surgical aortic valve replace-
ment (SAVR) in patients <70 years of age. Nonethe-
less, a recent study that examined surgically excised
aortic valves observed that one-ﬁfth of patients older
than 80 years of age had underlying bicuspid pathol-
ogy; echocardiography had identiﬁed only two-thirds
of these patients as having bicuspid morphology (4).SEE PAGE 2340
STS PROM = Society of
Thoracic Surgeons predicted
risk of mortality
TAV-in-BAV = transcatheter
aortic valve in bicuspid aortic
valve
TAVR = transcatheter aortic
valve replacement
TEE = transesophageal
echocardiography
THV = transcatheter heart
valve
VARC = Valve Academic
Research ConsortiumBAV has been excluded from the landmark clinical tri-
als involving transcatheter AVR (TAVR) (5,6). Theo-
retically, abnormal cusp fusion, pronounced
asymmetry of the valve oriﬁce and annulus, heavily
calciﬁed and ﬁbrotic leaﬂets, and calciﬁed raphe
(Figure 1) could have adverse effects on the expansion
of transcatheter aortic valves (TAV), ultimately lead-
ing to paravalvular aortic regurgitation (AR) and
poor hemodynamic function (7–9). The small number
of published case reports and series describing the
feasibility of TAV implantation in BAV stenosis
(TAV-in-BAV) have been limited in their demonstra-
tion of safety and efﬁcacy (10–16). Given the possibil-
ity that there are a signiﬁcant number of elderly
patients with BAV stenosis currently undergoing
TAVR and that there is a shift toward treating
younger patients with TAVR, a better understanding
of the clinical outcomes of patients subjected to
TAV-in-BAV is necessary (17,18).
This multicenter study sought to assess the safety
and efﬁcacy of TAV-in-BAV in a large group of patients.
More speciﬁcally, we sought to assess hemodynamic,
echocardiographic, and clinical outcomes, along with
the association between BAV morphology and TAV
prosthesis type on these aforementioned outcomes.
METHODS
PARTICIPATING CENTERS AND PATIENTS. The TAV-
in-BAV registry, a multinational collaboration ofis a proctor for Medtronic. Dr. Modine is a consultant for Medtronic, Gener
received institutional research grants from Edwards Lifesciences and Med
Lifesciences and Medtronic. Dr. Piazza is a proctor and consultant for Med
speaker honoraria from Medtronic and Edwards Lifesciences. Dr. Grube is a
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Manuscript received May 15, 2014; revised manuscript received July 17, 201interventional cardiologists and cardiac sur-
geons from high-volume TAVR centers, col-
lected data from patients who underwent
TAV-in-BAV from 12 participating centers
in Europe and Canada (Online Table 1). Data
have been prospectively collected since
October 2013. Patient selection for TAV-in-
BAV was performed at an institutional level,
following consideration of the risk proﬁle of
each case and discussions by the Heart Team.
In each case, centers submitted a dedicated
case report form detailing patient baseline
characteristics, echocardiographic and/or
multislice computed tomographic (MSCT)
data, procedural information, and scheduled
clinical follow-up.
BICUSPID AORTIC VALVE. BAV was deﬁned
as a spectrum of abnormal aortic valve
morphology consisting of 2 functional cusps
with less than 3 zones of parallel apposition
between cusps (19). BAV classiﬁcation was
assigned according to the number and spatial
orientation of the raphe (Figure 2). Type 0,
commonly referred to as “pure BAV,” has 2
normally developed cusps, sinuses, and commissures
and no raphe. Type 1 has 3 anlagen, 2 underdevel-
oped, and 1 fully developed cusps, 1 underdeveloped
commissure, 2 fully developed commissures, and 1
raphe whose orientation in relation to the sinuses
deﬁned subcategorization (left-right; right-non; and
left-non). Type 2 has 3 anlagen, 2 underdeveloped
cusps, 1 fully developed cusp, 2 underdeveloped
commissures, 1 fully developed commissure, and 2
raphe (19). Consistent with ﬁndings by prior publi-
cations, cases of commissural fusion with a raphe
<3 mm long were not considered to represent BAV
(20). All participating sites retrospectively conﬁrmed
the diagnosis and classiﬁcation of BAV using multi-
modal imaging: transthoracic and transesophageal
echocardiography (TEE) and MSCT. When both TEE
and MSCT were performed, cases were excluded if the
diagnosis of BAV was not consistent or remained
speculative.al Electric, and Boston Scientiﬁc. Dr. Windeker has
tronic; and has received lecture fees from Edwards
tronic. Dr. Sinning has received research grants and
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FIGURE 1 Bicuspid Aortic Valve Stenosis
Multislice computed tomography of a type 1 (left-right) bicuspid aortic valve. Axial (A), sagittal (B), and coronal (C) images demonstrate
the asymmetrical nature of the bicuspid aortic root.
FIGURE 2 Classiﬁc
Type 0
No raphe
Classiﬁcation of BAV
aortic valve; L ¼ left
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2332ENDPOINTS AND DEFINITIONS. Procedural, 30-day
mortality and other major clinical endpoints were
deﬁned according to the updated Valve Academic
Research Consortium (VARC) criteria (21). Of partic-
ular interest were the composite clinical endpoints of
valve efﬁcacy, safety, and success (21). Post-implant
AR represented an important nonclinical endpoint
(22). Regurgitation was deﬁned as the sum of trans-
valvular and paravalvular regurgitation following
prosthesis implantation and removal of the stiff
guidewire. At each institution, the severity of regur-
gitation was qualitatively assessed and graded using
TEE according to established guidelines (23,24).
Regurgitation was categorized as paravalvular,ation of BAV
Type 1
One raphe
Type 2
Two raphe
R – N  L – N
L – N / R – NL – R
according to the description of Sievers et al. (19). BAV ¼ bicuspid
coronary cusp; N ¼ non coronary cusp; R ¼ right coronary cusp.transvalvular, or mixed and was classiﬁed as none
(0), trace (I), mild (II), moderate (III), or severe (IV)
(23,24).
The dimensions of the aortic valve annulus were
measured using TEE or MSCT. TAV sizing was thus
deﬁned as either TEE- or MSCT-based. The ellipticity
ratio was determined using the formula “long/short-
axis” in patients who underwent MSCT analysis.
The cover index describes the amount of trans-
catheter heart valve (THV) oversizing relative to
native aortic annulus and was deﬁned by the
formula: ([{prosthesis diameter  annulus diameter}/
prosthesis diameter] 100) (25,26).
STATISTICS. Continuous variables are presented as
mean  SD, medians, and ranges and were compared
using Student t test, Mann-Whitney test, or paired t
test for repeated measures. Categorical variables are
presented as frequencies and percentages and were
compared using the chi-square or Fisher exact test.
Rates of 1-year mortality were shown using Kaplan-
Meier curves, and between-group differences were
analyzed with the log-rank test. Logistic regression
was performed with the entire cohort to identify
possible predictors of 1-year survival and post-
implantation AR. All variables that could plausibly
be associated with these outcomes were evaluated in a
univariate approach, and then factors with a p value
of <0.08 in the univariate analysis were combined in a
multivariate logistic regression model. A p value
of <0.05 was considered signiﬁcant. Analyses were
performed using SPSS version 20.0 (IBM Corp.,
Armonk, New York).
RESULTS
PATIENTS. A total of 139 elderly patients underwent
TAV-in-BAV across 12 participating centers between
TABLE 1 Baseline Characteristics
Characteristic
All Patients
(n ¼ 139)
Sapien
(n ¼ 48)
CoreValve
(n ¼ 91) p Value
Age, yrs 78.0  8.9 77.6  9.7 78.2  8.4 0.71
Males 78 (56.1) 30 (62.5) 48 (52.7) 0.29
BMI, kg/m2 25.7  5.8 26.5  6.9 25.3  5.2 0.25
Diabetes mellitus 34 (24.5) 14 (29.2) 20 (22.0) 0.41
NYHA functional class 3.0  0.6 3.0  0.5 2.9  0.6 0.33
NYHA functional class III/IV 114 (82.0) 44 (91.7) 70 (76.9) 0.04
Previous MI 26 (18.7) 9 (18.8) 17 (18.7) 0.99
Previous PCI 30 (21.6) 9 (18.8) 21 (23.1) 0.67
Previous CABG 14 (10.1) 5 (10.4) 9 (9.9) 0.99
Peripheral vascular disease 17 (12.2) 6 (12.5) 11 (12.1) 0.99
Previous stroke 8 (5.8) 4 (8.3) 4 (4.4) 0.45
Atrial ﬁbrillation 34 (24.5) 7 (14.6) 27 (29.7) 0.06
Pulmonary hypertension* 34 (24.5) 10 (20.8) 24 (26.4) 0.68
eGFR, ml/min 61.0  25.4 61.2  21.2 60.9  27.2 0.95
eGFR, #60 ml/min 70 (50.4) 23 (47.9) 47 (51.6) 0.74
STS PROM 4.9  3.4 5.0  3.9 4.8  3.1 0.96
Logistic EuroSCORE 14.8  10.6 15.3  10.7 14.5  10.7 0.68
EuroSCORE II 4.6  3.6 5.3  4.0 4.3  3.4 0.12
Echocardiography
Aortic valve mean gradient, mm Hg 48.7  16.5 49.9  15.5 48.1  17.1 0.54
Aortic valve area, cm2 0.6  0.2 0.7  0.2 0.6  0.2 0.006
Estimated annulus diameter, mm 23.2  2.3 24.2  2.4 23.2  3.7 0.09
LV ejection fraction, % 50.4  14.6 50.9  14.1 50.1  14.9 0.76
LV ejection fraction, #40% 41 (29.5) 13 (27.1) 28 (30.8) 0.70
MSCT aortic annulus dimensions†
Mean diameter, mm 24.5  3.4 24.0  2.2 24.7  3.9 0.25
Long diameter, mm 27.6  2.8 27.0  2.7 28.0  2.8 0.09
Short diameter, mm 22.2  2.5 21.6  2.3 22.7  2.5 0.04
Ellipticity ratio 1.25  0.12 1.26  0.12 1.24  0.12 0.44
Values are mean  SD or n (%). p Values represent comparisons between the balloon-expandable and self-
expandable valve prostheses. *Pulmonary artery systolic pressure $60 mm Hg. †Total of 88 patients under-
went MSCT analysis.
BMI ¼ body mass index; CABG ¼ coronary artery bypass graft; eGFR ¼ estimated glomerular ﬁltration rate;
LV ¼ left ventricle; MI ¼ myocardial infarction; MSCT ¼ multislice computed tomography; NYHA ¼ New York
Heart Association; PCI ¼ percutaneous coronary intervention; PROM ¼ predicted risk of mortality; STS ¼ Society
of Thoracic Surgeons.
TABLE 2 Bicuspid Aortic Valve Type
Valve Type
All Patients
(n ¼ 120)
Sapien
(n ¼ 40)
CoreValve
(n ¼ 80) p Value
Type 0 32 (26.7) 8 (20.0) 24 (30.0) 0.28
Type 1 82 (68.3) 31 (77.5) 51 (63.8) 0.15
LR 60 (50.0) 26 (65.0) 34 (42.5)
RN 15 (12.5) 2 (5.0) 13 (16.3)
LN 7 (5.8) 3 (7.5) 4 (5.0)
Type 2
LR/RN 6 (5.0) 1 (2.5) 5 (6.2) 0.66
Values are n (%). Classiﬁcation of bicuspid aortic valve morphology according to
Sievers et al. (19).
LN ¼ left - non; LR ¼ left - right; RN ¼ right - non.
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2333April 2005 and January 2014. Isolated stenoses
occurred in 91 patients (65.5%), isolated regurgitation
in 1 patient (0.7%), and mixed disease in 47 patients
(33.8%). The baseline demographics of the study
patients are outlined in Table 1. The mean age was
78.0  8.9 years, and the mean Society of Thoracic
Surgeons (STS) predicted risk of mortality (PROM)
score was 4.9  3.4%.
BICUSPID MORPHOLOGY. Evaluation of the mor-
phology of the aortic valve was performed using TEE
in all patients. MSCT was performed for the purpose
of sizing the TAV in 88 cases (63.3%). Among these
patients, the annuli were elliptical with an average
ellipticity ratio of 1.25  0.12. The BAV type was
deﬁnitively established in 120 patients (86.3%)
and remained uncertain in 19 patients (13.7%),
despite multimodal imaging. Among patients with a
conﬁrmed BAV type (Table 2), 32 patients (26.7%)
were type 0, 82 (68.3%) were type 1 (left-right: n ¼ 60;
right-non: n ¼ 15; and left-non: n ¼ 7), and 6 (5.0%)
were type 2. Diameter of the aortic sinuses (mean:
34.7  3.3 mm; range: 29 to 41 mm), root (mean: 32.7 
5.8 mm; range: 22 to 41 mm), and ascending aorta
(mean: 35.9  6.1 mm; range: 25 to 46 mm) indicated
that no patient had signiﬁcant ascending aortopathy.
PROCEDURES. Table 3 outlines the procedural
characteristics and results of the TAV-in-BAV
procedures. A balloon-expandable THV (SapienXT,
Edwards Lifesciences, Inc., Irvine, California)
(Figure 3) and self-expandable THV (CoreValve,
Medtronic, Inc., Minneapolis, Minnesota) (Figure 4)
were used in 48 patients (34.5%) and 91 patients
(65.5%), respectively. Transfemoral vascular access
was performed in 78.5% of cases, and pre-
implantation balloon aortic valvuloplasty was per-
formed in 98.6% of cases. A TAV was subsequently
implanted in 137 cases (98.6%). Of 2 patients who did
not receive a TAV, 1 case had severe aortic incompe-
tence and fatal cardiogenic shock following balloon
valvuloplasty (balloon-to-annulus ratio: 0.9), and in 1
case, the balloon-expandable valve failed to cross the
native aortic valve. The mean diameter of the
transcatheter valve was 27.8  2.2 mm and was
signiﬁcantly smaller in patients receiving the balloon-
expandable valve than in those receiving the self-
expandable THV (26.3  2.2 mm vs. 28.5  1.8 mm,
respectively; p ¼ 0.0002). Similarly, the cover index
was signiﬁcantly smaller in patients treated with the
balloon-expandable THV (8.9  5.7% vs 16.3  9.8%,
respectively; p < 0.0001). Post-implantation balloon
dilation was required in 25 cases (18.1%; balloon-
expandable THV n ¼ 5; self-expandable THV
n ¼ 20), and there were 3 (2.2%) episodes of TAVembolization (balloon-expandable THV n ¼ 2; self-
expandable THV: n ¼ 1). A second TAV was implan-
ted in 5 patients (3.6%; balloon-expandable THV
n ¼ 1; self-expandable THV n ¼ 4), and 3 cases (2.2%)
TABLE 3 Procedural Information and Outcomes
Characteristic
All Patients
(n ¼ 139)
Sapien
(n ¼ 48)
CoreValve
(n ¼ 91) p Value
TAV size, mm 27.8  2.2 26.3  2.2 28.5  1.8 0.0002
23 mm 10 (7.2) 10 (20.8) – –
26 mm 50 (36.0) 23 (47.9) 27 (29.7) 0.04
29 mm 59 (42.4) 15 (31.3) 44 (48.4) 0.07
31 mm 20 (14.4) – 20 (22.0) –
MSCT cover index, % 13.2  9.1 8.9  5.7 16.3  9.8 <0.0001
MSCT-based TAV sizing 88 (63.3) 37 (77.1) 51 (56.0) 0.02
Vascular access
Femoral 109 (78.5) 30 (62.5) 79 (86.8) 0.002
Subclavian 5 (3.6) – 5 (5.5) –
Apical 12 (8.6) 12 (25.0) – –
Aortic 12 (8.6) 6 (12.5) 6 (6.6) –
Carotid 1 (0.7) – 1 (1.1) –
General anesthesia 85 (61.1) 33 (68.8) 52 (57.1) 0.20
Balloon predilation 137 (98.6) 51 (100.0) 89 (97.8) 0.54
Predilation balloon size, mm 22.5  2.1 21.9  2.2 22.9  2.0 0.008
Balloon postdilation* 25 (18.1) 5 (10.6) 20 (22.2) 0.11
Postdilation balloon size, mm* 26.5  2.3 24.7  2.5 26.8  2.1 0.07
TAV malposition* 9 (6.5) 2 (4.3) 7 (7.8) 0.72
TAV embolization* 3 (2.2) 2 (4.3) 1 (1.1) 0.27
Need for 2nd TAV* 5 (3.6) 1 (2.1) 4 (4.4) 0.66
Tamponade 5 (3.6) 0 5 (5.7) 0.16
Aortic root rupture 1 (0.7) 1 (2.1) 0 –
Conversion to SAVR 3 (2.2) 2 (4.2) 1 (1.1) 0.30
Postimplantation echocardiography
Aortic regurgitation, grade (1–4)* 1.1  0.9 1.0  0.9 1.1  0.9 0.53
$Grade 2 38 (28.4) 9 (19.6) 29 (32.2) 0.11
$Grade 3 8 (6.0) 3 (6.5) 5 (5.5) 0.99
Aortic valve gradient, mm Hg* 11.4  9.9 11.7  8.7 11.3  10.4 0.82
Aortic valve area, cm2* 1.7  0.5 1.6  0.4 1.7  0.5 0.23
Contrast media, ml 174  88 176  118 172  81.5 0.17
Fluoroscopy duration, min 20 (14–28) 14 (9–25) 20 (15–29) 0.004
Values are mean  SD, n (%), or median (interquartile range). p values represent comparisons between the
Edwards Sapien and Medtronic CoreValve prostheses. *Refers to 137 patients who received a TAV.
MSCT ¼ multislice computed tomography; SAVR ¼ surgical aortic valve replacement; TAV ¼ transcatheter
aortic valve.
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n ¼ 2; self-expandable THV n ¼ 1). SAVR was required
for 1 annular rupture, 1 balloon-expandable THV
embolization, and 1 self-expandable THV malposi-
tion. Procedural mortality occurred in 5 patients
(3.5%) and was attributed to cardiac tamponade
resulting from guidewire perforation of the left ven-
tricle (n ¼ 2), major vascular complication, annular
rupture, and the case of severe AR following balloon
aortic valvuloplasty, as described previously.
CLINICAL OUTCOMES. The median duration of hos-
pital stay was 8 (interquartile range: 5 to 11) days
(Table 4). The 30-day rates of death, myocardial
infarction, and stroke were 5.0%, 2.2%, and 2.2%,
respectively. Any instance of bleeding occurred in 37
patients (26.6%), life-threatening bleeding occurredin 10 patients (7.2%), and major vascular complica-
tions occurred in 9 patients (6.5%). Overall, 110 pa-
tients (79.1%) met the combined safety endpoint, and
device success was observed in 125 patients (89.9%).
At 30 days, the combined efﬁcacy endpoint was ach-
ieved in 118 patients (84.9%).
Follow-up was available for all patients. At the
time of data lock, 136 patients (97.8%) and 129
patients (92.8%) had reached 6- and 12-month follow-
up examinations, respectively. The Kaplan-Meier
survival curve is shown in the Central Illustration.
There were 13 deaths (9.6%) at 6 months and 21
(17.5%) at 12 months; causes of death between 30 days
and 1 year (n ¼ 16) were congestive cardiac failure
(n ¼ 6), cancer (n ¼ 3), unknown (n ¼ 3), gastroin-
testinal hemorrhage (n ¼ 1), stroke (n ¼ 1), lung dis-
ease (n ¼ 1), and a road trafﬁc accident (n ¼ 1). On
multivariate analysis (Table 5), major vascular com-
plications were associated with increased 1-year
mortality (odds ratio [OR]: 5.66; 95% conﬁdence
interval [CI]: 1.21 to 26.43; p ¼ 0.03). At 1 year, 60.4%,
30.2%, and 9.4% of patients were assessed at
New York Heart Association (NYHA) functional class I,
II, or III, respectively.
POST-PROCEDURAL ECHOCARDIOGRAPHY. Among
the 137 patients who received a TAV, the mean aortic
valve gradient decreased from 48.7  16.5 mm Hg at
baseline to 11.4  9.9 mm Hg at 30 days (p < 0.0001),
whereas the mean aortic valve area increased from
0.6  0.2 cm2 at baseline to 1.7  0.5 cm2 at 30 days
(p < 0.0001). Post-implantation AR grade $2 (para-
valvular in 92% of cases) was present in 38 patients
(28.4%) at 30 days. When only those patients with
MSCT-based TAV sizing were considered, the inci-
dence of AR grade $2 was 17.4%. On multivariate
analysis, MSCT-based TAV sizing was independently
associated with a reduction in the incidence of post-
implantation AR grade $2 (OR: 0.19; 95% CI: 0.08 to
0.45; p < 0.0001) (Table 6). Male sex (OR: 4.29; 95%
CI: 1.63 to 10.79; p ¼ 0.003) was the only independent
predictor of increased AR grade $2. AR grade $2
occurred in 13.3% of BAV type 0 patients, 34.2% of
type 1, and 16.6% of type 2 (type 0 vs. type 1: p ¼
0.03).
PROSTHESIS CHOICE. Baseline characteristics among
patients treated with the balloon-expandable THV
were similar to those of patients who received
the self-expandable THV, although NYHA functional
class III or IV was more common in the balloon-
expandable valve cohort (p ¼ 0.04). MSCT-based TAV
sizing was also performed more frequently in the
balloon-expandable THV cohort (56.0% vs. 77.1%,
respectively; p ¼ 0.02), and the transfemoral
TABLE 4 Clinical Outcomes
Characteristic
All patients
(n ¼ 139)
Sapien
(n ¼ 48)
CoreValve
(n ¼ 91) p Value
Hospital stay, days 8 (5, 11) 7 (4, 12) 8 (6, 11) 0.38
Mortality
Procedural 5 (3.6) 1 (2.1) 4 (4.9) 0.66
At 30 days 7 (5.0) 3 (6.3) 4 (4.9) 0.69
At 6 months* 13 (9.6) 7 (14.6) 6 (6.6) 0.12
At 1 year† 21 (17.5) 10 (20.8) 11 (12.5) 0.12
Myocardial infarction 3 (2.2) 0 3 (3.3) 0.55
Periprocedural 3 (2.2) 0 3 (3.3) –
Spontaneous 0 0 0 –
Stroke 3 (2.2) 1 (2.1) 2 (2.2) 0.99
Disabling 2 (1.4) 1 (2.1) 1 (1.1) –
Non disabling 1 (0.8) 0 1 (1.1) –
Bleeding 37 (26.6) 8 (16.7) 29 (31.9) 0.07
Minor 18 (12.9) 2 (4.2) 16 (17.6) –
Major 9 (6.5) 4 (8.3) 5 (5.5) –
Life-threatening 10 (7.2) 2 (4.2) 8 (8.8) –
Acute kidney injury
(stage 3)
3 (2.2) 1 (2.1) 2 (2.0) 0.99
Vascular complications 30 (21.6) 6 (12.5) 24 (26.4) 0.08
Minor 21 (15.1) 2 (4.2) 19 (20.9) –
Major 9 (6.5) 4 (8.3) 5 (5.5) –
New pacemaker 32 (23.2) 8 (16.7) 24 (26.7) 0.21
Device success 125 (89.9) 43 (89.6) 82 (90.1) 0.99
Combined safety
endpoint
110 (79.1) 39 (82.2) 71 (78.0) 0.83
Combined efﬁcacy
endpoint
118 (84.9) 42 (87.5) 76 (84.5) 0.81
Values are n (%). Totals of 136* and 129† patients who reached 6-month or 1-year
follow-up examination, respectively.
SAVR ¼ surgical aortic valve replacement.
FIGURE 3 Newer Generation Balloon-Expandable TAV-in-BAV
TAV-in-BAV with a newer generation 29-mm balloon-expandable THV (Sapien XT,
Edwards Lifesciences). (A and B) Multislice computed tomography of bicuspid aortic valve
stenosis (type 1, RN). (C and D) Same patient after implantation with the newer generation
balloon-expandable valve. RN ¼ right - non; TAV-in-BAV ¼ transcatheter aortic valve
in bicuspid aortic valve; THV ¼ transcatheter heart valve.
FIGURE 4 Self-Expandable TAV-in-BAV
TAV-in-BAV with a 29-mm self-expandable THV (CoreValve; Medtronic). (A and B) Multi-
slice computed tomography of bicuspid aortic valve stenosis (type 1, LN). (C and D) Same
patient with the self-expandable valve. LN ¼ left - non; other abbreviations as in Figure 3.
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2335approach was more common among self-expandable
valve patients (p ¼ 0.002). There was a trend toward
an increased incidence of post-implantation AR
grade $2 among the self-expandable valve-treated
patients (19.6% vs. 32.2%, respectively; p ¼ 0.11).
When patients undergoing MSCT-based TAV sizing
were considered, the incidence of AR grade $2 was
similar between the 2 prostheses (6 of 37 [16.7%] vs. 9
of 50 [17.6%], respectively; p ¼ 0.99). The choice of
TAV was not associated with post-implantation AR in
multivariate analysis. There were no signiﬁcant dif-
ferences in procedural outcomes between patients
receiving the two types of valves. At 12 months, death
occurred in 10 patients who received the balloon-
expandable valve (20.8%) and in 11 self-expandable
valve recipients (12.5%; log-rank: p ¼ 0.46) (Central
Illustration).
DISCUSSION
This is the ﬁrst large multicenter analysis of TAV
implantation in patients with signiﬁcant BAV stenosis
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Kaplan-Meier survival curve of patients undergoing transcatheter aortic valve in bicuspid
aortic valve with the balloon-expandable THV (blue line) or self-expandable valve
(orange line) prostheses. The p value is the log-rank comparison between the 2 valves.
THV ¼ transcatheter heart valve.
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2336or regurgitation. We observed a 30-day mortality
rate of 5%, a 30-day stoke rate of 2%, and a device
success rate of 90%. One-year mortality was 17.5%,
and the patients were NYHA functional class I
or II. These results suggest that TAV-in-BAV is
feasible and associated with encouraging short- and
intermediate-term clinical outcomes. The current
analysis, however, demonstrated a high incidence of
post-implantation AR grade $2 (28.4%), although this
was reduced to 17% in those with MSCT-based TAV
sizing.
PROCEDURAL SAFETY AND EFFICACY. Treatment of
BAV disease with TAV technology is considered an
off-label indication. Surgically excised bicuspid
valves typically demonstrate leaﬂet fusion (raphe)
and extensive nodular calciﬁcation. The histo-
architectural distribution of calciﬁc deposits in BAV
leaﬂets is different from that of stenotic tricuspid
valves (27). Extensive calcium deposition in the body
of BAV leaﬂets and asymmetrical nature of the
bicuspid aortic root could impair TAVR outcomes
(19,28). Anecdotally, registry participants suggested
that guidewire crossing and THV positioning were
more difﬁcult with bicuspid than tricuspid aortic
valve stenosis. Nevertheless, the acute proceduralresults were acceptable, with acute TAV embolization
occurring in 2.2%, conversion to SAVR in 2.2%, and
encouraging 30-day rates of VARC-deﬁned device
success (89.9%), safety (79.1%), and efﬁcacy (84.9%).
These results are comparable to those reported for
TAVR in tricuspid aortic stenosis (5,6,29–32).
Traditionally, TAVR has been reserved for patients
at excessive or high risk for surgery (STS PROM
>10%). More recently, it has been recognized that
current risk models are ill equipped to accurately
gauge risk among TAVR recipients (33). TAVR tech-
nology is therefore being applied to patients at
lower predicted risk, following discussions by the
institutional heart team. In our study, the expected
30-day mortality (STS PROM) was 4.9%, indicting an
intermediate-risk cohort. We observed remarkable
similarities between expected and observed (5.0%)
30-day mortality rates. Mortality continued to
accrue, however, increasing to 17.5% at 1 year. By
comparison, Piazza et al. (34) performed a propensity-
matched analysis comparing TAVR to SAVR among
205 intermediate-risk patient pairs (STS PROM 3% to
8%) with severe tricuspid aortic valve stenosis. They
reported mortality in the TAVR and SAVR cohorts of
7.8 and 7.1%, respectively, at 30-days and 16.5 and
16.9%, respectively, at 1 year. One-year outcomes
in the current study compare favorably to those
reported for other TAV-in-BAV cohorts (11,15). The
1-year outcomes probably reﬂect the advanced age,
heavy burden of comorbidities, and other adverse
features inherent in TAVR cohorts that are not
captured by current risk prediction models (33). The
high rates of post-implantation AR also may have
inﬂuenced 1-year mortality (22).
POST-IMPLANTATION AR. In the current analysis, AR
grade $2 occurred in 28.4% of patients. This rate is
consistent with that reported in smaller TAV-in-BAV
series (13–15) and compares poorly with reported
rates (<20%) of AR following TAV for tricuspid aortic
valve stenosis (30,35,36). Notably, the incidence of
AR grade $2 was 17.4% when only patients who
underwent MSCT-based sizing were considered and
was similar between balloon- and self-expanding
prostheses (16.7% vs. 17.6%, respectively; p ¼ 0.99).
Consistent with prior studies (37,38), MSCT-based
TAV sizing was associated with reduced para-
valvular regurgitation and should be considered a
mandatory element of patient screening for TAV-in-
BAV. Nevertheless, MSCT-based TAV sizing is
unlikely to represent a panacea for post-implantation
AR in BAV because the unique anatomic features of
BAV pathology appear to present a challenge for
ﬁrst-generation TAVI systems. The TAV frame may
be unable to expand completely and appose to the
TABLE 5 Predictors of 1-Year Survival
Characteristic
Univariate Analysis Multivariate Analysis
Odds
Ratio 95% CI p Value
Odds
Ratio 95% CI p Value
Age 1.06 0.99–1.13 0.10
Males 1.15 0.45–3.95 0.77
STS PROM 1.06 0.94–1.19 0.38
Mean aortic gradient 1.00 0.97–1.03 0.94
Aortic valve area 0.08 0.01–1.50 0.09
LV ejection fraction <40% 1.14 0.42–3.08 0.80
Annulus size 1.03 0.88–1.19 0.74
TAV size 0.94 0.77–1.16 0.59
MSCT-based TAV sizing 1.32 0.49–3.55 0.58
Bicuspid type 1 1.29 0.45–3.69 0.63
CoreValve 0.44 0.17–1.15 0.08 0.38 0.14–1.04 0.06
Year of procedure 0.91 0.67–1.22 0.51
Diabetes 0.53 0.14–1.93 0.33
NYHA functional class II/III 2.57 0.56–11.85 0.23
Pulmonary hypertension 1.85 0.67–5.11 0.24
eGFR <60 1.44 0.56–3.69 0.45
TAV malposition 4.29 0.89–20.80 0.07 5.05 0.93–27.31 0.06
TAV embolization 5.30 0.32–88.27 0.25
Requirement for 2nd TAV 2.63 0.23–30.35 0.44
Major vascular complications 1.12 1.40–26.81 0.02 5.66 1.21–26.42 0.03
New pacemaker 0.73 0.23–2.36 0.61
AR grade $2 1.55 0.56–4.32 0.40
AR ¼ aortic regurgitation; CI ¼ conﬁdence interval; other abbreviations as in Table 1.
TABLE 6 Predictors of Aortic Regurgitation Grade $2
Characteristic
Univariate Analysis Multivariate Analysis
Odds
Ratio 95% CI p Value
Odds
Ratio 95% CI p Value
Age 0.95 0.96–1.03 0.63
Males 3.50 1.50–8.20 0.004 4.29 1.63–10.79 0.003
STS PROM 0.85 0.75–1.04 0.05 0.88 0.75–1.04 0.13
Mean aortic gradient 0.99 0.97–1.02 0.61
Aortic valve area 3.20 0.34–29.86 0.31
LV ejection fraction <40% 1.40 0.62–3.14 0.41
Annulus size 0.93 0.82–1.04 0.20
TAV size 1.10 0.92–1.31 0.31
MSCT-based TAV sizing 0.23 0.10–0.51 <0.0001 0.19 0.08–0.45 <0.0001
Bicuspid type 1 2.14 0.82–5.56 0.11
CoreValve 1.93 0.82–4.54 0.13
Year of procedure 0.78 0.60–1.03 0.08
Abbreviations as in Tables 1 and 5.
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2337native annulus in the presence of pronounced
annular ellipticity (mean ellipticity ratio: 1.25  0.12),
heavy calciﬁcation, and calciﬁed raphe. The latter
may have contributed to the increased rate of post-
implantation AR observed in patients with BAV type
1 compared with those with type 0 (34.2 vs. 13.3%,
respectively; p ¼ 0.03). Aortic root dilation and/or
angulation, as well as concomitant native aortic valve
incompetence, may further impede accurate TAV
positioning and contribute to the risk of paravalvular
regurgitation. Given the strong association between
post-procedural AR and both short- and long-term
mortality (22,35), the high incidence of AR observed
in BAV patients is disconcerting, and the suboptimal
echocardiographic outcomes mandate further longer
term follow-up to ascertain the clinical implications
of aortic incompetence in BAV cohorts.
COMPARISON WITH SAVR. Comparisons between
current study outcomes and those of historical sur-
gical series of patients undergoing isolated SAVR for
BAV disease are challenging. Most surgical series
included younger and lower-risk patients who do not
reﬂect the complexities of the current cohort (39,40).
Furthermore, such comparisons are also likely to be
confounded by considerable selection bias, whereas
in our study, each case was discussed by a dedi-
cated heart team whose members recommended
TAV-in-BAV rather than SAVR. Surgery, however,
should remain the treatment of choice for BAV
disease, especially in low-risk patients or in the pre-
sence of aortic root dilation. Ultimately, a random-
ized comparison between TAV-in-BAV and SAVR will
be required to prove equivalent safety and long-term
efﬁcacy.
CHOICE OF PROSTHESIS. BAV morphology presents
potential advantages and disadvantages for balloon-
and self-expanding TAV systems. The balloon-
expandable valve exerts greater radial force and
may circularize the native annulus, obliterating
potential sites of paravalvular AR. Calciﬁed nodules
or raphe, however, may impair complete prosthesis
expansion, thereby necessitating post-implantation
balloon dilation or, potentially, resulting in residual
paravalvular leakage. The self-expanding THV could
have greater propensity to such paravalvular regur-
gitation given the reduced radial strength relative to
balloon-expandable systems. The greater compliance
of self-expanding prostheses and the supra-annular
position of the leaﬂets could, however, mitigate the
unequal circular stress at the level of the annulus and
potentially improve long-term hemodynamic out-
comes. In our study, clinical outcomes among
patients treated with balloon expandable TAV were
similar to those observed in patients treated withthe self-expanding prostheses. We observed a trend
toward increased rates of post-implantation AR
grade $2 with the self-expandable THV; however, the
considerably lower use of MSCT-based TAV sizing in
the self-expandable THV cohort might have accounted
for this difference. Subgroup analysis of patients
undergoing MSCT-based TAV sizing demonstrated
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE 1:
TAVR of bicuspid aortic valves is associated with high
rates of grade $2 post-implantation
aortic regurgitation.
COMPETENCY IN MEDICAL KNOWLEDGE 2:
Sizing of the prosthesis based on measurements
obtained by multislice computed tomography can
reduce the likelihood of developing post-implantation
aortic regurgitation in patients with bicuspid aortic
valves undergoing TAVR.
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2338no signiﬁcant between-group differences in the rates
of post-implantation AR. Further study is required
to evaluate the comparative effectiveness of the
balloon-expandable and self-expandable valve sys-
tems in patients with BAV disease.
Currently unproven emerging TAV technology
with dedicated sealing cuffs (Sapien 3 [Edwards
Lifesciences]), repositionable systems (CoreValve
Evolut R [Medtronic], Portico [St. Jude Medical,
Minneapolis, Minnesota], or Lotus [Boston Scientiﬁc,
Natick, Massachusetts]) may have the potential to
reduce post-implantation AR (41–44).
STUDY LIMITATIONS. The study ﬁndings should be
interpreted in light of the study design. This pre-
dominantly retrospective voluntary registry of TAV-
in-BAV cases necessitates cautious interpretation,
and deﬁnitive conclusions should be avoided. The
exact indication for proceeding with TAV-in-BAV
rather than SAVR was not available for each
patient, although all cases were reviewed by the
institutional heart team. Adverse events and post-
implantation AR, which may be operator and labora-
tory dependent, were adjudicated by the participating
centers rather than by a core laboratory. Information
about the depth of implantation and invasive hemo-
dynamic data, such as the AR index, were not avail-
able in this study. The cover index and annular
ellipticity were not entered into the multivariate
regression because MSCT data were only available in
64% of patients.TRANSLATIONAL OUTLOOK: Further studies are
needed to determine whether later generation TAVR
devices reduce the risk of aortic regurgitation after
TAVR in patients with bicuspid aortic valves.CONCLUSIONS
TAV-in-BAV is feasible, with encouraging short-
and intermediate-term clinical outcomes. A highincidence of post-implantation aortic regurgitation is
observed following TAV-in-BAV. The incidence of
post-implantation paravalvular leak is moderated by
MSCT-based TAV sizing, which should be considered
mandatory for TAV-in-BAV. Longer-term follow-up of
a larger cohort of patients is required to more
completely assess the efﬁcacy and durability of TAV
implantation in patients with bicuspid disease.
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